No black box warning on record for Clenpiq

As of the latest FDA labeling reviewed, Clenpiq (SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID) does not carry a black box warning. Standard warnings and precautions still apply — see the full Clenpiq medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of fluid and electrolyte abnormalities, arrhythmia, seizures, and renal impairment : Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. ( 5.1 , 5.2 , 5.3 , 5.4 , 7.1 ) Use in patients with renal impairment or taking concomitant medications that affect renal function : Use caution, ensure adequate

No black box warning on record for Clenpiq

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of fluid and electrolyte abnormalities, arrhythmia, seizures, and renal impairment : Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. ( 5.1 , 5.2 , 5.3 , 5.4 , 7.1 ) Use in patients with renal impairment or taking concomitant medications that affect renal function : Use caution, ensure adequate

Clenpiq Black Box Warning

No black box warning on record for Clenpiq

Other warnings & precautions

Clenpiq Black Box Warning

No black box warning on record for Clenpiq

Other warnings & precautions